Clinical Trials

A Phase I/II Study of Crizotinib and STA-9090 in ALK-Positive Lung Cancers

Protocol
12-015
Full Title
A Phase I/II Study of Crizotinib and Ganetespib (STA-9090) in ALK Positive Lung Cancers
Purpose

Crizotinib is a drug that is approved for the treatment of non-small cell lung cancers (NSCLC) that contain an alteration in the ALK gene. In many patients, the response to crizotinib does not last, and the cancer begins to grow (on average, after less than a year on treatment). The purpose of this study is to see if adding the investigational drug STA-9090 can make crizotinib work better at preventing lung cancer from growing. STA-9090 works by blocking heat-shock protein 90 (Hsp90), which cancer cells need to grow and survive. Crizotinib is taken orally (by mouth). STA-9090 is given intravenously (by vein).

Investigator
Gregory J. Riely, MD, PhD; Vice Chair, Clinical Trials Office, Department of Medicine
Gregory J. Riely - Physician Profile
Co-Investigators
Paul K. Paik, MD
Paul K. Paik - Physician Profile
Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have stage III or IV NSCLC with a fusion of the EML4 and ALK genes.
  • Patients may not have previously received crizotinib, but may have had other chemotherapy.
  • Patients should have recovered from the side effects of prior therapies before entering the study.
  • Patients must be age 18 or older.

For more information about this study and to inquire about eligibility, please contact Dr. Gregory Riely at 646-888-4199.

Disease(s)
Lung Cancer
Lung Cancer, Non-Small Cell
Lung Cancer, Non-Small Cell: Lung Adenocarcinoma
Locations
ClinicalTrials.gov
Related Diseases